Losartan relieved dystrophic epidermolysis bullosa at least partly due to reducing the increased level of galectin-3 (31), thus inhibition of galectin-3 could be an additional mechanism of losartan in treating fibrosis. The gene discussed is LGALS3; the disease is Dystrophic epidermolysis bullosa.